Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients

Oncotarget. 2017 Mar 21;8(12):19760-19767. doi: 10.18632/oncotarget.15035.

Abstract

Objective: Previous studies have suggested a correlation between glucose transporter-1 (GLUT-1) expression and survival outcomes in pancreatic cancer, although the results were inconsistent. We subsequently carried out a meta-analysis, with the aim of comprehensively reevaluating the associations between GLUT-1 expression and overall survival (OS) and other clinical features of pancreatic cancer.

Results: Eight studies, with a total of 538 cases, were included in the final meta-analysis. The HR and 95% CI for OS were 1.79 and 1.19-2.7, respectively (p=0.005). GLUT-1 overexpression was associated with tumor size (>2 cm vs. ≤2 cm; OR=2.16, 95% CI=1.2-3.9, p=0.01) and lymph node metastasis (yes vs. no; OR=3.29, 95% CI=1.38-7.84, p=0.007). However, there was no significant association between GLUT-1 expression and histological grade, age, sex, TNM stage, or vascular invasion status. There was no evidence of significant publication bias in this meta-analysis.

Materials and methods: Relevant databases were searched using predefined searching items until September 2016. The pooled hazard ratios (HR) with 95% confidence interval (CI) for OS and the pooled odds ratio (OR) with 95% CI for clinical factors were calculated.

Conclusions: High GLUT-1 expression predicted shorter OS in patients with pancreatic cancer. Moreover, GLUT-1 expression was associated with a tumor size of >2 cm and presence of lymph node metastasis.

Keywords: biomarker; clinical; epidemiology; meta-analysis; pancreatic cancer.

Publication types

  • Meta-Analysis

MeSH terms

  • Aged
  • Female
  • Glucose Transporter Type 1 / biosynthesis*
  • Humans
  • Immunohistochemistry
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Outcome Assessment, Health Care / methods*
  • Outcome Assessment, Health Care / statistics & numerical data*
  • Pancreatic Neoplasms / metabolism*
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / surgery
  • Prognosis
  • Survival Analysis
  • Tumor Burden

Substances

  • Glucose Transporter Type 1